Distinct Short-Term Outcomes in Patients With Mild Versus Rapidly Improving Stroke Not Treated With Thrombolytics

被引:25
作者
Romano, Jose G. [1 ]
Smith, Eric E. [2 ]
Liang, Li [3 ]
Gardener, Hannah [1 ]
Campo-Bustillo, Iszet [1 ]
Khatri, Pooja [4 ]
Bhatt, Deepak L. [5 ]
Fonarow, Gregg C. [6 ]
Sacco, Ralph L. [1 ]
Schwamm, Lee H. [7 ]
机构
[1] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA
[2] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada
[3] Duke Clin Res Inst, Durham, NC USA
[4] Univ Cincinnati, Inst Neurosci, Cincinnati, OH USA
[5] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol,Dept Internal Med,Heart & Vasc Ctr, Boston, MA 02115 USA
[6] Univ Calif Los Angeles, Dept Internal Med, Div Cardiol, Los Angeles, CA 90024 USA
[7] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA
关键词
dyslipidemias; National Institutes of Health; outcome assessment (health care); risk factors; stroke; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; INTRAVENOUS THROMBOLYSIS; GUIDELINES-STROKE; SCALE SCORES; SYMPTOMS; ELIGIBILITY; RECOVERY; DEFICITS; REGISTRY;
D O I
10.1161/STROKEAHA.115.011528
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Mild stroke (MS) and rapidly improving stroke (RIS) symptoms are common stroke presentations. Our objective is to describe the short-term outcomes in this population. Methods-A retrospective analysis of patients with ischemic stroke in the Get With The Guidelines-Stroke registry who arrived 4.5 hours from symptom onset not treated with thrombolytics because of MS and RIS. Outcomes included in-hospital death, home discharge, independent ambulation at discharge, and length of stay; these were analyzed for the categories of MS, RIS, and MS+RIS. Multivariable models evaluated the associations of individual and hospital covariates with outcomes. Results-Among 42 394 patients with MS and RIS not treated with thrombolytics, 27% were not discharged directly home, 27.2% did not ambulate independently, and 61.1% had length of stay 3 days, despite a low in-hospital mortality of 0.8%. Adjusted outcomes were better for MS+RIS compared with MS; RIS also had better independent ambulation and home discharge compared with MS. Among those with a documented National Institutes of Health Stroke Scale, 25% of those with National Institutes of Health Stroke Scale 0 to 5 and half of those with National Institutes of Health Stroke Scale >5 could not be discharged directly to home or ambulate independently. Older individuals, women, blacks, transport by ambulance, delayed arrival, greater severity and greater burden of vascular risk factors, except for dyslipidemia, had worse adjusted outcomes for home discharge and independent ambulation. Conclusions-A significant proportion of patients with MS and RIS not treated with thrombolytics have suboptimal discharge outcomes. We found significant differences between MS, RIS, and MS+RIS and identified factors associated with worse outcomes.
引用
收藏
页码:1278 / 1285
页数:8
相关论文
共 34 条
[1]   Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility [J].
Barber, PA ;
Zhang, J ;
Demchuk, AM ;
Hill, MD ;
Buchan, AM .
NEUROLOGY, 2001, 56 (08) :1015-1020
[2]   Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke [J].
Christou, I ;
Alexandrov, AV ;
Burgin, WS ;
Wojner, AW ;
Felberg, RA ;
Malkoff, M ;
Grotta, JC .
STROKE, 2000, 31 (08) :1812-1816
[3]   What Causes Disability After Transient Ischemic Attack and Minor Stroke? Results From the CT And MRI in the Triage of TIA and minor Cerebrovascular Events to Identify High Risk Patients (CATCH) Study [J].
Coutts, Shelagh B. ;
Modi, Jayesh ;
Patel, Shiel K. ;
Aram, Heidi ;
Demchuk, Andrew M. ;
Goyal, Mayank ;
Hill, Michael D. .
STROKE, 2012, 43 (11) :3018-3022
[4]   Long-Term Functional Recovery After First Ischemic Stroke The Northern Manhattan Study [J].
Dhamoon, Mandip S. ;
Moon, Yeseon Park ;
Paik, Myunghee C. ;
Boden-Albala, Bernadette ;
Rundek, Tatjana ;
Sacco, Ralph L. ;
Elkind, Mitchell S. V. .
STROKE, 2009, 40 (08) :2805-2811
[5]   What Is a Minor Stroke? [J].
Fischer, Urs ;
Baumgartner, Adrian ;
Arnold, Marcel ;
Nedeltchev, Krassen ;
Gralla, Jan ;
De Marchis, Gian Marco ;
Kappeler, Liliane ;
Mono, Marie-Luise ;
Brekenfeld, Caspar ;
Schroth, Gerhard ;
Mattle, Heinrich P. .
STROKE, 2010, 41 (04) :661-666
[6]  
George Mary G., 2009, Morbidity and Mortality Weekly Report, V58, P1
[7]   High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo-controlled trial [J].
Ginsberg, Myron D. ;
Palesch, Yuko Y. ;
Hill, Michael D. ;
Martin, Renee H. ;
Moy, Claudia S. ;
Barsan, William G. ;
Waldman, Bonnie D. ;
Tamariz, Diego ;
Ryckborst, Karla J. .
LANCET NEUROLOGY, 2013, 12 (11) :1049-1058
[8]   Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke [J].
Hacke, Werner ;
Kaste, Markku ;
Bluhmki, Erich ;
Brozman, Miroslav ;
Davalos, Antoni ;
Guidetti, Donata ;
Larrue, Vincent ;
Lees, Kennedy R. ;
Medeghri, Zakaria ;
Machnig, Thomas ;
Schneider, Dietmar ;
von Kummer, Ruediger ;
Wahlgren, Nils ;
Toni, Danilo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) :1317-1329
[9]   Why are eligible thrombolysis candidates left untreated? [J].
Hills, Nancy K. ;
Claiborne Johnston, S. .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2006, 31 (06) :S210-S216
[10]   Intravenous Tissue Plasminogen Activator for Patients with Minor Ischemic Stroke [J].
Huisa, Branko N. ;
Raman, Rema ;
Neil, Will ;
Ernstrom, Karin ;
Hemmen, Thomas M. .
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2012, 21 (08) :732-736